Indeed, up to 80% of all melanomas harbor activating NRAS or BRAF mutations8,9, with BRAFV600E representing more than 90% of BRAF mutations, resulting in constitutive activation of the signaling pathway, promoting melanoma proliferation and resistance to apoptosis10. Here, NRAS is linked to melanoma.